2d illustrations and photos Maze Therapeutics (MAZE), which is developing treatments for chronic kidney disease, has filed to raise $100M through an initial public offering. While the company didn't disclose terms in its SEC filing , it indicated in a filing fee schedule that it.
Back to Health Page
